Magipics has produced a biomedical animation for Aravax describing the mechanism of action of PVX108, a next generation immunotherapy for the treatment of peanut allergy.
As stated on the Aravax website (aravax.com.au): “Aravax is a clinical-stage biotechnology company developing the first safe, convenient and disease-modifying treatment for peanut allergy. Aravax uses proprietary technology to precisely reset the immune system to tolerate allergens without evoking allergic reactions during treatment. The company is headquartered in Melbourne, Australia.
Following successful Phase 1 trials, Aravax’s lead product PVX108 has received FDA clearance to commence Phase 2 clinical trials in the United States. PVX108 is being developed to become the first safe and convenient treatment for peanut allergy.”
Mats Bjorklund at Magipics has a strong scientific background in molecular biology and cell biology with a PhD in Biotechnology. Creating accurate visuals illustrating complex biomedical topics such as these are thus easily handled.
The animation can be viewed on the Aravax website.